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Available online 23 October 2015In inﬂammatory autoimmune diseases, bone loss is frequent. In most cases, secondary osteoporosis is caused by
treatment with systemic glucocorticoid. However, the pathogenesis behind the bone loss is presumed
multifactorial.
We aimed to elucidate the role of the P2X7 receptor on bonemineral density (BMD),microarchitecture, and bone
strength in a standardized mouse model of inﬂammation-mediated osteoporosis (IMO).
In total 146mice completed our protocol, 70wild type (WT)mice and 76 P2X7−/− (knockout, KO). BMD at the
femur and spine decreased signiﬁcantly frombaseline to day 20 in theWT IMOmice (p b 0.01). In theWTvehicle,
KO vehicle and KO IMO, no signiﬁcant BMD changes were found.
Bone strength showed a lower mid-shaft max strength (p = 0.038) and also a non-signiﬁcant trend towards
lower strength at the femoral neck of the WT IMO group. Trabecular bone volume fraction (BV/TV) and connec-
tivity density (CD) after 20 days were signiﬁcantly decreased in the WT IMO group (p= 0.001). In contrast, the
WT vehicle and KO vehicle, BV/TV and CD did no change at 20 days. Cortical bone revealed no signiﬁcant
microarchitectural changes after 20 days in the WT IMO group, whereas the total cortical area increased signiﬁ-
cantly in WT vehicle and KO IMO after 20 days (5.2% and 8.8%, respectively).
In conclusion, the P2X7 receptor KO mice did not respond to inﬂammation with loss of BMD whereas the WT
mice had a signiﬁcant loss of BMD, bone strength and trabecular microarchitecture, demonstrating a role for
the P2X7 receptor in inﬂammatory bone loss.
© 2016 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Microarchitecture1. Introduction
Autoimmune diseases and other chronic inﬂammatory diseases are
often complicated by osteoporosis; 10% of rheumatoid arthritis patients
are osteoporotic and 25% are osteopenic (Goldring, 2003; Guler-Yuksel
et al., 2007). Several factors are known to inﬂuence the risk of bone loss
and several of those are often present in patients suffering inﬂammatory
diseases i.e. medications, physical inactivity and endocrine factors. Glu-
cocorticoids are widely used in the treatment of inﬂammatory autoim-
mune diseases, and it is well known that the use of glucocorticoids is
associated with osteoporosis (Weinstein, 2011). Glucocorticoid-
induced osteoporosis (GIO) is the second most common form of osteo-
porosis and the most common iatrogenic form of the disease
(Weinstein, 2011). However, a meta-analysis has shown an increaseding and Osteoporosis, Dep. of
ospitalet, Denmark.
z).
en access article under the CC BY-NCincidence of osteoporosis in rheumatoid arthritis patients even after
correcting for the use of glucocorticoids (Mundy, 2007).
Patients suffering from active inﬂammatory diseases may also have
chronically impaired physical activity. This relative immobility can fur-
ther contribute to the bone loss in patients with inﬂammatory diseases.
Also, endocrine factors affecting the calcium and bone homeostasis
might inﬂuence the bone remodeling leading to bone loss i.e. low estro-
gen level, high plasma PTH and low plasma 25-OH-vitamin D. However,
the inﬂammatory process itself may induce changes in the regulation of
bone turnover that consequentlymay lead to systemic bone loss. The in-
ﬂammatory autoimmune diseases include a group of disorders that
share the presence of inﬂammatory and destructive changes that affect
the structure and function of articular and periarticular tissues. Several
proinﬂammatory cytokines (such as Tumor Necrosis factor alpha
(TNFα), interleukin (IL)-1 and IL-17) are major triggers for osteoclast
activation explaining the enhanced bone loss during inﬂammation.
Other, such as IL-12, IL-18, IL-33 and interferon alpha2 (IFN), are strong
suppressors of osteoclast differentiation and inhibit bone loss. Thus the-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ﬂammation triggers bone loss or not (Solle et al., 2001).
In recent years, the role of adenosine triphosphate (ATP) and its cog-
nate receptors in the inﬂammatory process has been recognized. In par-
ticular, the P2X7 receptor which is expressed on the immune cells and
bone cells (Collo et al., 1997) is thought to play an important role in
macrophage/microglial and granulocyte function by regulating cytokine
production and apoptosis (Bours et al., 2011; Kvist et al., 2014). More-
over, as the P2X7 receptor is known to be up-regulated during inﬂam-
mation, antagonists of this receptor may serve as novel anti-
inﬂammatory agents (Alves et al., 2013; Lister et al., 2007). Lister et al.
have summarized recent advances in the understanding of the role of
the P2X7 receptor in inﬂammatory processes and highlight the poten-
tial of P2X7 receptor ligands for the treatment of chronic inﬂammatory
diseases (Lister et al., 2007). In the immune system, this receptor has
been implicated in the processing and release of cytokines such as IL-
1β, and in the initiation of cell death via both apoptotic and necrotic
pathways (Lister et al., 2007; Chen and Brosnan, 2006; Dubyak, 2012;
Qu et al., 2007). As such, it has been proposed to function as amajor reg-
ulator of inﬂammation. Experiments performed in vitro and in vivo in
P2X7 receptor null mice demonstrated this receptor to be responsible
for ATP-dependent IL-1β release (Solle et al., 2001; Gartland et al.,
2003). Furthermore, the P2X7 receptor seems also implicated in the re-
lease of many other cytokines (Lister et al., 2007). In bone, the P2X7 re-
ceptor hasmultiple actions. It is expressed in both osteoblasts (Gartland
et al., 2001; Grol et al., 2009) and osteoclasts (Hoebertz et al., 2000;
Naemsch et al., 2001). It is involved in intercellular communication
among osteoblasts (Jorgensen et al., 1997, 2000). In mouse osteoblasts,
P2X7 receptor activation induces blebbing of the plasma membrane
(Panupinthu et al., 2007). Moreover, P2X7 receptors have been shown
to mediate extra cellular signal-regulated kinase (ERK) 1/2 activation
by ﬂuid shear stress (Okumura et al., 2008). Thus, P2X7 receptors in os-
teoblastic cells couple to multiple signaling pathways, some of which
are important in skeletal mechanotransduction.
Osteoclasts seem to consistently express P2X7 receptors. In osteo-
clasts, the P2X7 receptor has amore complex role where it has been im-
plicated in cell fusion (Gartland et al., 2003), apoptosis (Penolazzi et al.,
2004), the translocation and activation of NFΚB (nuclear factor kappa-
light-chain-enhancer of activated B cells) (Korcok et al., 2004) and pro-
tein kinase C (PKC) (Armstrong et al., 2009) and intercellular communi-
cation (Jorgensen, 2005).
Consistent with the above, inactivation of the receptor in micemod-
ulates disease pathogenesis in several animal models of inﬂammatory
and autoimmune diseases (Chen and Brosnan, 2006). The aim of this
study was therefore to investigate the role of the P2X7 receptor in in-
ﬂammatory mediated bone loss in a mouse model of generalized
inﬂammation.
2. Material and methods
2.1. Animals
The study protocol was in compliancewith the bioethical guidelines
for animal research and was approved by the Danish Animal Experi-
ments Inspectorate (Protocol: 2010/561-1907).
In total 146 mice ﬁnalized the study protocol, 70 WT mice and 76
P2X7−/− (KO). Initially eight weeks old mice breeding pairs
P2X7−/− on a C57bl/6 background from Jackson Laboratories (Bar
Harbor, ME) were obtained and the intended breeding goal was 75
male P2X7−/− mice. Seventy male C57bl/6fBomTac wild type (WT)
mice 14 weeks of age from BOM (Taconic, Lille Skensved, Denmark)
were included as control animals. The animals were kept in a 12 h
light/dark cycle with light on at 8 am. The animals were fed ad libitum
with standard diet (1319F Altromin) and had free access to drinking
water (domestic quality tap water). The ﬂow and study groups are pre-
sented in Fig. 1.2.2. The inﬂammation-mediated osteoporosis model (IMO)
We induced chronic inﬂammation by subcutaneous implantation of
a non-speciﬁc irritant, TALC according to the method ﬁrst published
Minne et al. (1984) and further standardized by Armour and Armour
(2003).
The animals were weighed and anaesthetised using Hypnorm/
dormicum doses 3 μL/g. Using a 21-23 G needle, TALC suspension
800 mg/mL or vehicle was injected subcutaneously (s.c.) to a total
dose of 16 mg/g body weight. One injection of TALC was injected in
each side of the animal lateral to the spine spreading out the suspen-
sion in the length of the needle. Hereafter Calcein (0.8 mg/mL) was
injected intraperitoneally (20 mg/kg) 10 and 2 days before sacriﬁce.
The mice were kept fasting over night before sacriﬁce. On the day of
sacriﬁce themicewere anaesthetized and euthanized by cervical dis-
location. Blood was drawn by cardiac puncture before cervical dislo-
cation. The blood samples were coagulated for about 10 min before
centrifuged and serum stored at−20 °C. The body weight was mea-
sured, BMDwasmeasured by DXA-scanning on a PIXImus DXA appa-
ratus (Lunar Corp., Madison, WI, USA) in duplicate measurements
and spleen was removed and weighted. The spine and hind legs
were isolated and were cleansed of soft tissue. Right femur was
stored wrapped in saline gaze and frozen to −20 °C. The spleen
and right tibia together with ﬁbula were stored in ethanol. Entire
left leg and spine were stored in 10% formalin and weight of the
spleen was measured.
2.3. Analysis
2.3.1. Bone mineral density (BMD) by dual X-ray absorptiometry (DXA)
BMD, bone mineral content (BMC) and bone area measurements
were performed using a Lunar Piximus densitometer (Lunar Corp.,
Madison, WI). The total spine was chosen as Region of Interest
(ROI) spanning from just above os sacrum. The femur was also chosen
as a ROI spanning from caput to proximal to the condyles above
the knee joint. Left femur was chosen, but if TALC interfered
with the ROI the right femur was used. The spine was re-scanned
in duplicate (4–5 lowest vertebral bodies), having been stored in 10%
formalin. Data were analysed using the manufacturer's software
(version 2.0).
2.3.2. Biomechanical testing (Bone strength)
Prior to mechanical testing the bones were thawed and rehydrated
to approximately 20 °C in saline 1 day before testing. Bone strength
measurements were made using the Lloyd LR 50 k (Lloyd Instruments,
Fareham, UK). They were performed as a 3-point bending test at the
femoral mid-shaft and as a vertical compression test on the femoral
head (Syberg et al., 2012).
Load-deformation curveswere generated, andmaximal loadwas re-
corded at a speed of 2 mm per minute with a 100 N load cell. Ultimate
load is the maximal load (N) the bone can resist before it breaks.
2.3.3. Micro-CT scanning and microarchitectural analysis
The femurs and tibiae of mice were dissected free of soft tissue, and
stored in 10% formalin. The mid-shaft and the proximal part of left tibia
were scanned using a high-resolution micro computed tomography
(micro-CT) system (vivaCT 40, Scanco Medical AG, Brüttisellen,
Switzerland). The baseline and the 20 day groups of WT and KO were
scanned. The scan resulted in a 3-dimensional (3D) reconstruction of
cubic voxel sizes of 10.5 ∗ 10.5 ∗ 10.5 μm3 (2048 ∗ 2048 ∗ 2048 pixels)
with 32-bit gray levels. Each 3D image dataset consisted of approxi-
mately 210 CT slide images. For proximal tibial cancellous bone, 100
slide images (1050 μm)beneath the growth platewere used for analysis
of cancellous bone microarchitecture. For mid-shaft cortical bone, all
210 slice images were used for analysis of cortical microarchitecture
Fig. 1. Flow diagram and group design of 146 mice included in the study.
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analysed.
Using direct 3D methods the following measures were performed:
Bone volume fraction (BV/TV, %), trabecular number (Tb.N, per mm),
trabecular thickness (TbTh, mm), trabecular separation (Tb.Sp, mm),
connectivity density (Conn D, mm−3) and structural model index
(SMI,−) were calculated. From the cortical data bone porosity (%), cor-
tical thickness (mm), BS/TV (mm−1), pore size (mm), total cross-
sectional area (Tt.ar, mm2), cortical area (Ct.Ar, mm2) and cortical area
fraction (%) were measured or calculated (Ding et al., 2012a, b).
2.3.4. Cytokine measurements
The concentrations (pg/mL) of cytokinesweremeasured in serum in
duplicates using a commercial kit: Mouse ProInﬂammatory 7-Plex
Ultra-Sensitive Kit (Meso scale Discovery: Rockville). The measure-
ments were performed at the Center of Inﬂammation and Metabolism,
Copenhagen University Hospital, Rigshospitalet in accordance with
manufacturer's instructions. The coefﬁcient of variationwas at low, me-
dium and high concentrations IL1b: 8.4%; 1.8% and 3.2% (highest at low-
est concentration), IL-12: 8.1%; 2.3% and 4.4%, IFN-y: 7.3%; 1.0% and
2.9%, IL-6: 2.8%; 6.8% and 4.0%; KC/GRO: 7.8%; 5.7% and 2.8%; IL-10:
4.3%; 1.1% and 5.8% and TNFα: 9.0%; 3.4% and 2.6%.
The lower limits of detection (LLOD) were: IL1b: 0.75 pg/mL; IL-12:
35 pg/mL; IFN-y: 0.38 pg/mL; IL-6: 4.5 pg/mL; KC/GRO: 3.3 pg/mL; IL-
10: 11 pg/mL and TNFα: 0.85 pg/mL.
2.3.5. Markers of bone turnover
In order to investigate the effect of generalized inﬂammation and
P2X7 receptor expression on bone turnover, serum markers of bone
formation (total pro-collagen type 1 N-terminal propeptide (P1NP)
and C-terminal telopeptide of type 1 collagen (CTX-1)) weremeasured.
P1NPwasmeasured in serum samples in duplicate using the Rat/mouse
P1NP assay from IDS (Immunodiagnostic systems PLC, Boldon, OK) fol-
lowing the protocol supplied. P1NP: precision: intra assay: 5–7.4%.
Inter-assay: 9.2-8%. CTX-1was measured in serum samples in duplicate
using the RATlaps EIA assay from IDS (Immunodiagnostic systems PLC)
using the suppliers instructions. Intra-assay variation: CV was 9.2-5.8%,
Inter-assay variation: CV: 14.8–10.7%.2.4. Statistics
SPSS software version 19was used. Standard parametric tests, T-test,
ANCOVA and ANOVA were used as appropriate. On data unlikely to be
normally distributed or with a lower sample size non parametric
Mann-Whitney tests were used. Differences were considered statistical-
ly signiﬁcant when p b 0.05. Simple descriptives were presented as
means ± standard deviation (SD) or standard error of the mean (SEM).
3. Results
The study included in total 146 mice (Fig. 1).
At baseline, the bodyweight differed slightly between WT animals
and KO mice, (28.3 ± 1.77 g vs. 31.1 ± 2.4 g, p b 0.002). We observed
no signiﬁcant difference between WT vehicle animals compared to
WT IMO mice and KO vehicle animals compared to KO IMO animals.
Furthermore, we observed no signiﬁcant change in body weight during
the 10 and 20 days of the experiment; and no difference between the
vehicle and IMO groups in both WT and KO animals.
The spleenweight was 86.4± 13.2mg in theWT animals compared
to 104.3 ± 27 mg in the KO animals at baseline. The spleen weight in-
creased signiﬁcantly in the WT IMO mice to 131 ± 59 mg; p b 0.005)
at day 10 and to 130.8±44.4; p b 0.001 at day 20, whereaswe observed
no signiﬁcant change in spleenweight in theWTvehicle, KOvehicle and
KO IMO mice at 10 and 20 days.
3.1. Bone mineral density (BMD)
BMD at the femur and spine decreased signiﬁcantly from baseline to
day 20 in the WT IMO mice (p b 0.01) (Table 1). After correction for the
lower weight of the WT mice compared to KO mice the reduction was
still signiﬁcant (p= 0.032). In the WT vehicle, KO vehicle and KO IMO
no signiﬁcant BMD changeswere found frombaseline to day 20 (Table 1).
3.2. Bone strength
In Table 2 the data on bone strength measurements are
presented. The data showed increased mid-shaft max strength in WT
Table 1
Bonemineral densitymeasured by DXA inWT and KOmice at baseline, vehicle and IMO at
10 and 20 days. Statistical comparison was made between baseline and day 10 as well as
baseline and 371 day 20.
BMD g/cm2 Baseline
Mean (SD)
10 days
Mean (SD)
20 days
Mean (SD)
WT vehicle Total 0.0515
(0.0018)
0.0519
(0.0019)
0.0534
(0.0015)
Femur 0.0736
(0.0047)
0.0739
(0.0040)
0.0739
(0.0035)
Spine 0.0488
(0.0034)
0.0532
(0.003)
0.0508
(0.0025)
WT IMO Total 0.0515
(0.0018)
0.0579
(0.0035)
0.0545
(0.0044)
Femur 0.0736
(0.0047)
0.0726
(0.0049)
0.0695*
(0.0050)
Spine 0,0488
(0.0034)
0.0490
(0.0037)
0.0460*
(0.0057)
KO vehicle Total 0.0521
(0.0020)
0.0531
(0.0017)
0.0539
(0.0016)
Femur 0,0707
(0.0052)
0.0733
(0.0039)
0.0747
(0.0033)
Spine 0.0520
(0.0041)
0.0516
(0.0037)
0.0513
(0.0034)
KO IMO Total 0.0521
(0.0020)
0.0560
(0.0027)
0.0530
(0.0023)
Femur 0.0707
(0.0052)
0.0739
(0.0040)
0.732
(0.0030)
Spine 0.0520
(0.0041)
0.0539
(0.0014)
0.0520
(0.0043)
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mid-shaft strength of the KO vehicle group at 20 days. In contrast no in-
crease was observed in WT IMO (Table 2).Table 3A
Comparison of 3-D microarchitectural parameters of trabecular bone in 4 groups.
3-D microarchitecture Baseline
Mean (SD)
20 days
Mean (SD)
p-value
WT vehicle BV/TV (%) 23.5 (4.0) 23.4 (3.2) ns
Tb.N (per mm) 4.64 (0.59) 4.60 (0.54) ns
Tb.Th (mm) 0.06 (0.01) 0.070 (0.01) 0.052
Tb.Sp (mm) 0.19 (0.06) 0.21 (0.03) ns
Conn.D (mm−3) 158.4 (23.1) 139.5 (25.4) 0.06
SMI (−) 1.57 (0.31) 1.48 (0.26) ns3.3. Bone microarchitecture
TheMicro-CTdata of trabecular bone showed that bone volume frac-
tion (BV/TV) after 20 days was signiﬁcantly decreased in the WT IMO
group (28.1%, p=0.001). The trabecular space was signiﬁcantly higher
(28.0%, p b 0.001) and the trabecular number lower (13.1%, p=0.017).
In contrast, the WT vehicle and KO vehicle BV/TV, trabecular space and
trabecular number did not change at 20 days. The KO IMO did as
well not change in BV/TV, but trabecular number signiﬁcantly de-
creased (8.0%, p = 0.019) and trabecular space increased at 20 days
(8.7%, p = 0.041) to a less extend compared to WT IMO (Table 3A).
Representative changes are also shown in Fig. 2.
The Micro-CT data of cortical bone showed no signiﬁcant changes in
cortical bone area after 20 days in theWT IMO group, whereas the total
bone area increased signiﬁcantly in WT vehicle in KO IMO group after
20 days (5.2% and 8.8%, respectively). The mean 2d cortical bone area
fractionwas also lower in the 20 daysWT IMO group compared to base-
line (p= 0.005), (Table 3B).Table 2
Biomechanical bone strength measurements in WT and KO mice at baseline, vehicle and
IMO at 10 and 20 days.
Max bone
strength (MPa)
Baseline
Mean (SD)
20 days
Mean (SD)
p-value
WT vehicle Midt-shaft 19.1 (2.0) 20.9 (2.0) 0.028
Femoral neck 17.5 (2.7) 17.1 (1.3) ns
WT IMO Midt-shaft 19.1 (2.0) 19.0 (2.4) ns
Femoral neck 17.5 (2.7) 16.3 (2.4) ns
KO vehicle Midt-shaft 19.1 (2.6) 19.8 (1.3) ns
Femoral neck 16.4 (2.7) 17.3 (2.7) ns
KO IMO Midt-shaft 19.1 (2.6) 20.0 (1.5) ns
Femoral neck 16.4 (2.7) 18.5 (2.2) ns3.4. Cytokine measurements
Serum samples were available in sufﬁcient amount enabling cyto-
kine measurements from 117 of the 146 animals. However, 40 samples
were lost due to technical error leaving only between 7 and 15 samples
in each group. A substantial part of the cytokine measurements were
below Lower limit of detection or below curve ﬁt. On IL-1β, TNF-α and
IL-12measurements data were generally lower than themeasurements
limits (data not shown), e.g. only 11 of the IL-12 measurements were
not lower than the limit of detection (LLOD) or below curve ﬁt (being
lower than the lowest measurement for the standard curve and there-
fore measurements cannot be estimated).
In WT vehicle none of the measured cytokines changes signiﬁcantly
after 10 or 20 days compared to WT baseline. In KO vehicle only IL-10
was signiﬁcantly increased at 20 days compared to KO baseline. In WT
IMO - IL-10was signiﬁcantly higher at 20 days and IL-6was signiﬁcantly
higher at 10 days compared to baseline. In KO IMO - IL-6 was signiﬁ-
cantly higher at 10 and 20 days (Table 4A) compared to baseline. Com-
paring WT and KO in their corresponding groups, IMO 10 days, IMO
20 days, vehicle 10 days and vehicle 20 days: IL 10 was lower at base-
line; at 10 days vehicle both Cxcl1 and IL-10 was different; at 10 days
IMO IL-10 was different; at 20 days no differences were found between
the cytokines comparing WT and KO in both IMO and vehicle
(Table 4A). In the WT Comparing IMO and vehicle at 10 and 20 days
only 20 days IL-10 was signiﬁcantly higher in IMO WT (p= 0.006).3.5. Bone turnover markers
In theWT vehicle CTX-I was signiﬁcantly higher at 20 days and P1NP
was signiﬁcantly lower at 10 and 20 days (p b 0.001) compared to base-
line. No differences were found in the WT IMO comparing 10 and
20 days to baseline. In KO vehicle P1NP was signiﬁcantly lower at
10 days compared to baseline and in the KO IMO CTX-I was signiﬁcantly
lower at 20 days compared to baseline. Comparing WT and KO in their
corresponding groups found both CTX-I and P1NP signiﬁcantly lower
at baseline. At 20 days vehicle CTX-I was signiﬁcantly lower and P1NP
was higher in the KO compared to the WT. At 20 days IMO the CTX-I
and P1NP was lower than in the KO. In the 10 day groups only P1NPWT IMO BV/TV (%) 23.5 (4.0) 16.9 (5.1) 0.001
Tb.N (per mm) 4.64 (0.59) 4.03 (0.59) 0.017
Tb.Th (mm) 0.06 (0.01) 0.061 (0.01) ns
Tb.Sp (mm) 0.19 (0.03) 0.25(0.04) b0.001
Conn.D (mm−3) 158.4 (23.1) 106.7 (31.3) b0.001
SMI (−) 1.57 (0.31) 1.87 (0.39) 0.042
KO vehicle BV/TV (%) 23.3 (4.0) 23.2 (3.4) ns
Tb.N (per mm) 5.28 (0.33) 4.99 (0.49) ns
Tb.Th (mm) 0.06 (0.004) 0.06 (0.005) ns
Tb.Sp (mm) 0.18 (0.01) 0.18 (0.03) ns
Conn.D (mm−3) 167.0 (23.9) 157.9 (26.8) ns
SMI (−) 1.48 (0.18) 1.38 (0.33) ns
KO IMO BV/TV (%) 23.3 (4.0) 22.4 (4.0) ns
Tb.N (per mm) 5.28 (0.33) 4.86 (0.47) 0.019
Tb.Th (mm) 0.06 (0.004) 0.06 (0.004) ns
Tb.Sp (mm) 0.18 (0.01) 0.20 (0.02) 0.041
Conn.D (mm−3) 167.0 (23.9) 140.5 (19.9) 0.006
SMI (−) 1.48 (0.33) 1.38 (0.33) ns
Fig. 2. Representative 3D bone architecture WT and KO mice at baseline, vehicle 20 days and IMO 20 days.
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(Table 4B). Comparing between IMO and vehicle P1NPwas signiﬁcantly
lower inWT IMO at 20 days (P=0.002). P1NPwas lower in 10 days KO
vehicle compared to IMO (p = 0.04) but was borderline higher at
20 days (p=0.05). No differences were found comparing CTX-I vehicle
and IMO groups in WT or KO.
4. Discussion
The P2X7 receptor is a key factor in inﬂammatory responses and as
the receptor is also important in the regulation of bone formation and
resorption, we hypothesized that the receptor plays an important role
in the inﬂammatory bone loss. Our results showed that the P2X7 recep-
tor might play a signiﬁcant role in the bone loss associated with the
chronic inﬂammation in a mouse model of generalized inﬂammation.
The bone loss seen in WT IMO animals was completely abolished in
P2X7 KO animals; this was true for both BMD and for the trabecular
microarchitectural parameters. This implies that the role of the receptor
is different in bone that is not exposed to chronic inﬂammation and
bone in inﬂammatory diseases. In previous studies on P2X7 receptor ef-
fects in bone, P2X7 KOs have decreased bonemass compared toWT – in
our study there is a bone-protective effect of not expressing the P2X7
receptor. The explanation for thismight be the role of the P2X7 receptor
in the inﬂammatory response where P2X7 receptor activation has been
shown to up-regulate expression of and activate the NALP3
inﬂammasome.Moreover, P2X7 KOmice have reduced cytokine release
and attenuated inﬂammatory response compared to WT animals (Solle
et al., 2001). The cytokines TNFα, IL-1, IL-6 and IL-17 are known major
triggers of osteoclasts and IL-12, IL-18, IL-33 and IFN are strong suppres-
sors of osteoclast differentiation and inhibit bone loss (Schett, 2011). In
contrast, regulation of “normal” bone metabolism happens in anenvironment without low grade inﬂammation and with low levels of
cytokines, and the effect of the P2X7 receptor in bone cells might there-
fore prevail compared to the effect of the receptor in the immune
system.
A few published studies on experimentally induced inﬂammation
have shown to induce osteoporosis, though no model completely
mimics autoimmune disease in humans. The IMO model was chosen
as it gives a robust inﬂammatory response and as it has been shown
to develop osteoporosis (Armour and Armour, 2003). However, the
exact mechanisms of the inﬂammatory response are relatively un-
known though they might involve activation of the inﬂammasome
complex in which the P2X7 receptor is a key factor. In our study, we
found a decrease in BMD and in BV/TV in the WT IMO mice while the
WT vehicle treated animals maintained their bone mass and structure.
Also, spleen weights in the WT IMO animals were increased after
20 days, indicating a clear activation of the immune system. These ﬁnd-
ings are in linewith previousﬁndings from studies using thismodel and
document the reproducibility of thismodel and the validity of our study.
Amour et al. found that TALC signiﬁcantly increased the NO production
(2.5-fold, p b 0.005) in WT mice with IMO, but observed no change in
iNOS KO mice. In contrast, iNOS KO mice with IMO showed less inhibi-
tion of bone formation than WT mice and showed no signiﬁcant in-
crease in osteoblast apoptosis. The authors concluded that inducible
NOS-mediated osteoblast apoptosis and depressed bone formation
might play important roles in the pathogenesis of their model
(Armour et al., 2001).
A number of the P2X7-coupled pathways are important in both the
immune response and in the control of bone resorption, as bone resorp-
tion is increased signiﬁcantly in inﬂammatory-induced bone loss. Dur-
ing the inﬂammatory process large amounts of ATP are released; ATP
is a natural ligand for most P2 receptors and an inﬂammation-induced
Table 4B
Bone turnover markers, *p b 0.05, 10 and 20 days vs. baseline. #p b 0.05 comparing
between KO/WT in corresponding groups. £p b 0.05 comparing between IMO and vehicle
in corresponding groups KO or WT.
Bone markers
(serum)
Baseline Mean
(±SEM)
10 days Mean
(±SEM)
20 days Mean
(±SEM)
WT vehicle CTX ng/mL 62.4 (8.1)# 50.6 (7.6) 88.5 (8.2)*/#
P1NP pg/mL 67.1 (6.7) 53.2 (3.8)# 36.7 (2.8)*/#/£
WT IMO CTX ng/mL 62.4 (8,1)# 56.4 (7.0) 76,7 (8.1)#
P1NP pg/mL 67.1 (6,7) 51.2 (6.3) 54.2 (3.7)#/£
KO vehicle CTX ng/mL 29.4 (4.4)# 46.1 (8.3) 19.4 (2.2)#
P1NP pg/mL 49.1 (5.1) 32.7 (3.8)*/#/£ 54.9 (4.5)#/£
KO IMO CTX ng/mL 29.4 (4.4)# 59.2 (12.3) 18.1 (2.2)*/#
P1NP pg/mL 49.1 (5.1) 42.9 (4.7)£ 40.4 (1.2)#/£
Table 3B
Comparison of 3-D microarchitectural parameters and cross-sectional areas of cortical
bone in 4 groups.
Baseline
Mean (SD)
20 days
Mean (SD)
p-value
WT Vehicle 3-D microarchitecture
Porosity (%) 2.40 (0.14) 1.92 (0.09) 0.009
Cort.Th (mm) 0.24 (0.01) 0.25 (0.00) ns
BS/TV (mm−1) 3.50 (0.16) 4.31 (0.13) ns
Pore size (mm) 0.04 (0.01) 0.04 (0.01) ns
2-D cross-sectional area
Tt.Ar (mm2) 2.28 (0.05) 2.40 (0.04) ns
Ct.Ar (mm2) 1.17 (0.02) 1.24 (0.01) 0.008
Ct.Ar/Tt.Ar (%) 51.46 (0.7) 52.21 (1.2) ns
WT IMO 3-D microarchitecture
Porosity (%) 2.40 (0.14) 2.53 (0.20) ns
Cort.Th (mm) 0.24 (0.01) 0.21 (0.14) ns
BS/TV (mm−1) 3.50 (0.16) 4.16 (0.28) ns
Pore size (mm) 0.04 (0.01) 0.06 (0.03) ns
2-D cross-sectional area
Tt.Ar (mm2) 2.28 (0.05) 2.32 (0.07) ns
Ct.Ar (mm2) 1.17 (0.02) 1.13 (0.04) ns
Ct.Ar/Tt.Ar (%) 51.46 (0.7) 48.45 (0.7) 0.005
KO Vehicle 3-D microarchitecture
Porosity (%) 2.00 (0.10) 1.93 (0.16) ns
Cort.Th (mm) 0.23 (0.00) 0.23 (0.01) ns
BS/TV (mm−1) 4.30 (0.13) 4.28 (0.10) ns
Pore size (mm) 0.02 (0.01) 0.02 (0.01) ns
2-D cross-sectional area
Tt.Ar (mm2) 2.11 (0.06) 2.39 (0.04) 0.004
Ct.Ar (mm2) 1.06 (0.03) 1.143 (0.01) 0.025
Ct.Ar/Tt.Ar (%) 50.47 (0.8) 47.97 (1.1) ns
KO IMO 3-D microarchitecture
Porosity (%) 2.00 (0.10) 2.20 (0.15) ns
Cort.Th (mm) 0.23 (0.00) 0.23 (0.00) ns
BS/TV (mm−1) 4.30 (0.13) 4.00 (0.20) ns
Pore size (mm) 0.02 (0.01) 0.03 (0.01) ns
2-D cross-sectional area
Tt.Ar (mm2) 2.11 (0.06) 2.30 (0.04) 0.012
Ct.Ar (mm2) 1.06 (0.03) 1.12 (0.01) ns
Ct.Ar/Tt.Ar (%) 50.47 (0.8) 48.97 (0.8) ns
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the P2X7 receptor which requires high concentrations of ATP to be acti-
vated. As ATP is rapidly degraded extracellularly, systemically increased
levels of ATP are unlikely. Skeletal effects of ATP-mediated purinergic
signaling through P2X7 receptors may therefore occur via threemecha-
nisms. Theﬁrst is the general skeletal bone loss,whichmight be induced
through local activation of P2X7 receptors on immune cells inducing IL-Table 4A
Cytokine measurements, *p b 0.05, compared to baseline. #p b 0.05 comparing between
KO/WT in corresponding groups. £p b 0.05 comparing IMO and vehicle in corresponding
groups, WT or KO. 3 measurements or lower resulted in data coded as missing. LLOD de-
notes Lower limit of detection at 50% or more.
Cytokines
pg/mL
Baseline Mean
(±SEM)
10 days Mean
(±SEM)
20 days Mean
(±SEM)
WT vehicle Cxcl1 47.6 (4.7) 47.9 (13.6)# 46.1 (4.8)
IFN 2.3 (0.6) 2.7 (1.1) 2.1 (0.4)
IL10 21.0 (3.0)# 20.0 (2.3)# 18.2 (1.7)£
IL6 38.2 (14.1) 82.6 (31.0) 71.3 (11.2)
WT IMO Cxcl1 47.6 (17.1) 54.3 (8.2) 54.9 (6.9)
IFN 2.3 (0.6) 2.0 (0.5) 1.7 (0.1)
IL10 21.0 (3.0)# 23.0 (3.5) 28.1 (2.3)£
IL6 38.2 (14.1) 96.5 (20.9)* 57.2 (11.6)
KO vehicle Cxcl1 67.3 (11.2) 63.5 (6.4)# 56.9 (5.5)
IFN 2.0 (1.0) 5.2 (1.6) –
IL10 10.2 (1.0)# 14.0 (2.0)# 20.1 (2.6)*
IL6 20.9 (10,2) 43.6 (15,4) 46.0 (12,5)
KO IMO cxcl1 67.3 (11) 66.4 (13.6) –
IFN 2.0 (1.0) – –
IL10 10.2 (1.0)# 14.8 (4.6) –
IL6 20.9 (10.2) 100.3 (51.4)* 90.8 (35.0)*1β and TNF-α production, processing and release to the circulation
where it induces a generalized increase in bone resorption through ac-
tivation of osteoclasts in all parts of the skeleton. Secondly, ATP release
as part of the inﬂammatory process could activate bone cells locally as
the immune system and bone are in close contact both in the bonemar-
row and in affected joints. Here, activation of P2X7 receptors in bone
cells could activate osteoclasts both through a direct activation of oste-
oclast precursors to formmature multinucleated bone-resorbing osteo-
clasts and through an indirect activation via stimulation of osteoblastic
P2X7 receptors and upregulation of RANKL on osteoblasts, thereby in-
ducing osteoclast formation and activity. Finally, due to reduced mobil-
ity of patients due to their primary inﬂammatory diseases, a reduced
activation of P2X7 receptors in osteoblasts, usually mediating
mechanotransduction and anabolic effects, results in reduced bone for-
mation, which further aggravates the effects of the disease on the
skeleton.
The question then arises whether altered P2X7 receptor function in
humans affect the risk of inﬂammatory-induced bone loss. This has
been has been addressed in a recent study by Portales-Cervantes et al.
(2010), where the authors examined the association between polymor-
phisms in the P2X7 receptor and the risk of rheumatoid arthritis or sys-
temic lupus erythematosus. Even though they were not able to
demonstrate differences in the distribution of genotypes between pa-
tients and healthy controls, they found affected receptor function and
cytokine production in cells from both rheumatoid arthritis patients
and systemic lupus erythematosus patients, suggesting a possible in-
volvement of the receptor in the pathogenesis in autoinﬂammatory dis-
eases (Portales-Cervantes et al., 2010). However, the study did not
address the role of the receptor in the inﬂammatory bone loss, neither
did it include a full genotyping for all known functional P2X7 receptor
polymorphisms. Based on our in vivo ﬁndings, loss-of-function poly-
morphisms might be expected to protect against autoimmune diseases
and the associated bone loss. This is in contrast to what has been shown
in normal, healthy subjects, where we have demonstrated that loss-of-
function of the receptor is associated with increased bone loss and in-
creased fracture risk in humans while gain-of-function polymorphisms
in the receptor were associated with increased bone mass and reduced
fracture risk (Gartland et al., 2012; Jorgensen et al., 2012; Ohlendorff
et al., 2007). However, no studies have so far examined the association
between chronic inﬂammatory diseases and the risk or severity of
bone loss in humans and such studies are highly warranted.
We believe that our study provides evidence for the effects of the
P2X7 receptor in inﬂammatory bone loss, as the ﬁndings are consistent
over a range of evaluation methods. Both BMD, bone microstructure,
and bone strength all points to the same conclusion.
Furthermore, the cytokine data on IL 6 support that inﬂammation is
induced in themodel used. Thus, the suppressed bone loss in KOmouse
demonstrates that the P2X7 receptor is responsible for inﬂammatory-
mediated bone loss in this model. However, our study has also some
limitations, especially that the data on serum bone markers in total
are inconclusive and thus does not support neither increased nor
151T.M. Kvist et al. / Bone Reports 7 (2017) 145–151suppressed bone loss. Our data on IL-1b and bone turnover markers
were expected to support the observations on BMD, bone microstruc-
ture, bone strength and IL-6. However, measuring cytokines are well
known for their low half-life, and changes in cytokine levels are expect-
ed throughout the experiment. Our results showed IL-1b below the
level of detection in all situations which might be a limitation of our
study. We are limited by the low blood volume in mice, and cardiac
puncture was therefore chosen to maximize the available serum. Cardi-
ac puncture is however difﬁcult. It is likely that stress and tissue damage
has some impact depending on the duration and skill of our technique
in cardiac puncture. Cardiac puncture as well as hypnorm-dormicum
injection could also affect especially cytokine.
In conclusion, our study is the ﬁrst to demonstrate the effects of the
P2X7 receptor on bone in chronic inﬂammation.We found that ablation
of the P2X7 receptor KO in a mouse model of IMO protected against in-
ﬂammatory bone loss andmaintained bone strength in the animals. The
potential implications for patients with inﬂammatory diseases are evi-
dent. However, studies in humans are needed to further clarify the asso-
ciation between P2X7 receptor function and autoimmune bone loss.
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